Literature DB >> 26330877

Warfarin-induced Eosinophilia in a Child with urkitt Lymphoma: A Case Report.

Kourosh Goudarzipour1, Farid Ghazizadeh1, Hesameddin Hoseini Tavassol1, Behdad Behnam2.   

Abstract

An important complication of chemotherapy is thromboembolic events that can occur during treatment course. In this way, Warfarin can be used as an efficient prophylactic agent to prevent these complications. Although bleeding is a common adverse effect of Warfarin, eosinophilia is a rare side effect of this drug. We have reported a 5-year-old boy with Burkitt lymphoma who underwent chemotherapy. In the course of chemotherapy, because of thrombosis of the left jugular vein, we initiated Warfarin as a prophylactic drug for TEE secondary to chemotherapy. Following Warfarin initiation, eosinophilia appeared and subsequent to cessation of drug, eosinophilia disappeared. This case is presented to point out physicians to consider eosinophilia as a rare adverse-effect of Warfarin and monitor blood cell differentiation regularly during the course of treatment with this drug.

Entities:  

Keywords:  Anticoagulant therapy; Burkitt lymphoma; Eosinophilia; Pediatrics; Warfarin

Year:  2015        PMID: 26330877      PMCID: PMC4518117     

Source DB:  PubMed          Journal:  Iran J Pharm Res        ISSN: 1726-6882            Impact factor:   1.696


  7 in total

1.  A case of warfarin-induced eosinophilia.

Authors:  Masakazu Teragaki; Hitomi Kawano; Ryojiro Makino; Keisuke Inoue; Yoshinori Sai; Mitsuharu Hosono; Shigefumi Suehiro; Mikio Okamura
Journal:  Intern Med       Date:  2012-06-15       Impact factor: 1.271

Review 2.  Eosinophils in the 1990s: new perspectives on their role in health and disease.

Authors:  A J Wardlaw
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

3.  Eosinophilia associated with Coumadin.

Authors:  D Hall; K Link
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

Review 4.  Warfarin therapy: evolving strategies in anticoagulation.

Authors:  J D Horton; B M Bushwick
Journal:  Am Fam Physician       Date:  1999-02-01       Impact factor: 3.292

5.  Warfarin-induced eosinophilic pleurisy.

Authors:  T Kuwahara; M Hamada; Y Inoue; S Aono; K Hiwada
Journal:  Intern Med       Date:  1995-08       Impact factor: 1.271

6.  Eosinophilic presentation of acute lymphoblastic leukemia.

Authors:  Azim Rezamand; Ziaaedin Ghorashi; Sona Ghorashi; Nariman Nezami
Journal:  Am J Case Rep       Date:  2013-05-08

7.  Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin.

Authors:  Shahideh Amini; Kheirollah Gholami; Hooman Bakhshandeh; Bahram Fariborz Farsad
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  7 in total
  2 in total

1.  Urbanization and anticoagulant poisons promote immune dysfunction in bobcats.

Authors:  Laurel E K Serieys; Amanda J Lea; Marta Epeldegui; Tiffany C Armenta; Joanne Moriarty; Sue VandeWoude; Scott Carver; Janet Foley; Robert K Wayne; Seth P D Riley; Christel H Uittenbogaart
Journal:  Proc Biol Sci       Date:  2018-01-31       Impact factor: 5.349

2.  A One-pot Condensation for Synthesis 2-methyl-4-phenylpyrano[3, 2-c] chromen-5(4H)-one and Synthesis of Warfarin by Ionic Liquid Catalysis.

Authors:  Aazam Monfared; Zohreh Esmaeeli
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.